LIJI SURRAO: Open Payments
NPI 1962118802 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$848 in 39 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $247 · 2025 $848
Food & beverage: $816Education: $32
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $267 |
| ABBVIE INC. | 6 | $129 |
| AstraZeneca Pharmaceuticals LP | 4 | $92 |
| Lilly USA, LLC | 3 | $63 |
| Dexcom, Inc. | 1 | $42 |
| Exact Sciences Corporation | 2 | $42 |
| Corcept Therapeutics | 1 | $26 |
| Amgen Inc. | 1 | $26 |
| Insulet Corporation | 1 | $25 |
| Iovance Biotherapeutics, Inc. | 1 | $24 |
Products named: Ozempic, VRAYLAR, Wegovy, Dexcom G6 Transmitter, Cologuard Collection Kit, LINZESS, JARDIANCE, FARXIGA.
Industry payments across IL — which companies pay providers there.
